IMMH-010 is under clinical development by Tianjin Chase Sun Pharmaceutical and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IMMH-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IMMH-010 is under development for the treatment of solid tumor and non-small cell lung cancer (NSCLC). It is administered through oral route. It acts by targeting programmed cell death 1 ligand 1.
Tianjin Chase Sun Pharmaceutical overview
Tianjin Chase Sun Pharmaceutical (Chase Sun) is a medicine and healthcare company. The company research develops, produces, and markets various pharmaceutical products. It offers products such as Chinese medicinal granules, finished drugs, raw materials, medical instruments, and pharmaceutical equipment. The company also provides medical and healthcare services. Its pharmaceutical product are used for the treatment of systemic inflammatory response syndrome (SIRS), sepsis (Sepsis), multiple organ dysfunction syndromes (MODS) and others. Chase Sun is headquartered in Tianjin, China.
For a complete picture of IMMH-010’s drug-specific PTSR and LoA scores, buy the report here.